Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04016610 · ClinicalTrials.gov registry record · NA
Proof of Concept (POC) Study of the Soliton's Acoustic Scar Reduction (ASR) Treatment for the Treatment of Keloid Scar
A NA study, sponsored by Soliton.
- Completed
- Registry status
- NA
- Development phase
- 9
- Enrollment target
NCT04016610: Completed NA study, sponsored by Soliton.
NCT04016610 is a NA study that has completed, run by Soliton. The registered enrollment target is 9 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04016610, a NA study, has completed, sponsored by Soliton.
- COMPLETED
- Registry status
- NA
- Development phase
- 9 participants
- Enrollment target
Study Summary
To evaluate the safety, and efficacy of the ASR device for the temporary improvement in the appearance of a keloids.
Primary Outcome
The safety endpoint will be met if all treated participants are free from unexpected adverse events and serious adverse events directly attributable to the ASR device or treatment.
Interventions
- DEVICE Soliton's Acoustic Scar Reduction (SAR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2019-07-09 |
| Est. Completion | 2020-02-12 |
| Phase | NA |
What the finished NCT04016610 record still lists
NCT04016610 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Soliton's Acoustic Scar Reduction (SAR) is the first listed.
NCT04016610 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04016610 about?
NCT04016610 is a clinical study titled "Proof of Concept (POC) Study of the Soliton's Acoustic Scar Reduction (ASR) Treatment for the Treatment of Keloid Scar". To evaluate the safety, and efficacy of the ASR device for the temporary improvement in the appearance of a keloids.
What is the current status of trial NCT04016610?
This trial is currently completed. It is a NA study. The enrollment target is 9 participants. The study started on 2019-07-09. Estimated completion is 2020-02-12.
What interventions are being tested in trial NCT04016610?
The interventions under investigation include: Soliton's Acoustic Scar Reduction (SAR) (DEVICE).
Who is sponsoring clinical trial NCT04016610?
This trial is sponsored by Soliton, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04016610's enrollment target sits among peer trials
9 1975th of 2000 higher than 25 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI